Keywords: GlaxoSmithKline, Maxinutriton, MeiRui, Stiefel, M&D, Zacks

Zacks analysts view GlaxoSmithKline’s recent acquisition spree, but CEO sees slow down in M&A

Article | 15 December 2010

Print This

Analysts at US financial services group Zacks Investment Research have issued a note reviewing UK drug giant GlaxoSmithKline’s ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in